METCrusaders· @metcrusaders · X·· 10 小时前评分70
正文 · 原文
#ESMO26 | Dr. Rebecca Heist (@MGHThoracicOnc) highlighted 3 Phase III trials supporting EGFR + MET inhibition after resistance: SACHI, SAFFRON & dalmelitinib/aumolertinib.
Key questions remain: How should MET positivity be defined, and which patients benefit most?
#METCrusaders #NSCLC #LungCancer #EGFR #MET #lcsm
0 赞 · 0 转发 · 0 回复
来源：METCrusaders · x.com